Yang Kaiying,Peng Suhua,Qiu Tong,et al.Clinical study of oral propranolol treatment of infantile hepatic hemangioma[J].Journal of Clinical Pediatric Surgery,,19():145-149.[doi:10.3969/j.issn.1671-6353.2020.02.011]
Clinical study of oral propranolol treatment of infantile hepatic hemangioma
- Keywords:
- Propranolol; Liver; Hemangioma/DT; Treatment Outcome; Child
- CLC:
- R726;R732.2;R735.7
- Abstract:
- Objective To assess the efficacy of propranolol treatment for infantile hepatic hemangioma (IHH).Methods A retrospective study of symptomatic or potentially symptomatic IHH was conducted between 2013 and 2018.Results There were 4 boys and 11 girls.Hepatomegaly (60%) was the predominant clinical presentation.Twelve (80.0%) patients had cutaneous infantile hemangiomas.Hypothyroidism (n=5) and congestive heart failure (n=1) were noted.The lesions were diffuse (n=2) and multifocal (n=13),including ’combined’ (n=2).All but one child responded well to propranolol dosing.One non-responder died from congestive heart failure and abdominal compartment syndrome.Eight children stopped dosing during a mean duration of therapy of 23.8(18.0-30.0) months.The remaining 6 patients on propranolol therapy had a mean treatment duration of 20.5(6.0-41.0) months.The average size of maximum tumor was 15.12 cm3 pre-treatment.At 6 and 12 months post-dosing,the average size of maximal tumor was 6.49 cm3 and 3.56 cm3 respectively.And Ⅴ/Ⅵ treatment response (desizing ≥ 50%) were observed in 53.3% and 83.3% at 6 and 12 months post-treatment respectively.As compared with initial treatment,propranolol dosing was associated with a dramatic sizing decline at 6 and 12 months (P<0.05).The mean follow-up period was 29.5(2.0-48.0) months.Recurrent IHH and significant side effects of propranolol were not observed during follow-ups.Conclusion Most IHH cases respond well to oral propranolol dosing.And propranolol is an alternative option for IHH due to its definite efficacy and great safety.
References:
1 Hsi Dickie B,Fishman SJ,Azizkhan RG.Hepatic vascular tumors[J].Semin Pediatr Surg,2014,23(4):168-172.DOI:10.1053/j.sempedsurg.2014.06.018.
2 Iacobas I,Phung TL,Adams DM,et al.Guidance Document for Hepatic Hemangioma (Infantile and Congenital) Evaluation and Monitoring[J].J Pediatr,2018,203:294-300.e2.DOI:10.1016/j.jpeds.2018.08.012.
3 Gnarra M,Behr G,Kitajewski A,et al.History of the infantile hepatic hemangioma:From imaging to generating a differential diagnosis[J].World J Clin Pediatr,2016,5(3):273-280.DOI:10.5409/wjcp.v5.i3.273.
4 Christison-Lagay ER,Burrows PE,Alomari A,et al.Hepatic hemangiomas:subtype classification and development of a clinical practice algorithm and registry[J].J Pediatr Surg,2007,42(1):62-68.DOI:10.1016/j.jpedsurg.2006.09.041.
5 Kulungowski AM,Alomari AI,Chawla A,et al.Lessons from a liver hemangioma registry:subtype classification[J].J Pediatr Surg,2012,47(1):165-170.DOI:10.1016/j.jpedsurg.2011.10.037.
6 Roebuck D,Sebire N,Lehmann E,et al.Rapidly involuting congenital haemangioma (RICH) of the liver[J].Pediatr Radiol,2012,42(3):308-314.DOI:10.1007/s00247-011-2268-z.
7 Krowchuk DP,Frieden IJ,Mancini AJ,et al.Clinical Practice Guideline for the Management of Infantile Hemangiomas[J].Pediatrics,2019,143(1).DOI:10.1542/peds.2018-3475.
8 曲志博,刘连新.小儿肝脏血管瘤的诊疗进展[J].临床小儿外科杂志.2016,15(4):393-396.DOI:10.3969/j.issn.671-6353.2016.04.024. Qu ZB,Liu LX.Advances in the diagnosis and treatment of infantile hepatic hemangioma[J].J Clin Ped Sur,2016,15(4):393-396.DOI:10.3969/j.issn.1671-6353.2016.04.024.
9 Haggstrom AN,Drolet BA,Baselga E,et al.Prospective study of infantile hemangiomas:clinical characteristics predicting complications and treatment[J].Pediatrics,2006,118(3):882-887.DOI:10.1542/peds.2006-0413.
10 Ji Y,Wang Q,Chen S,et al.Oral atenolol therapy for proliferating infantile hemangioma:A prospective study[J].Medicine (Baltimore),2016,95(24):e3908.DOI:10.1097/MD.0000000000003908.
11 Rialon KL,Murillo R,Fevurly RD,et al.Risk factors for mortality in patients with multifocal and diffuse hepatic hemangiomas[J].J Pediatr Surg,2015,50(5):837-841.DOI:10.1016/j.jpedsurg.2014.09.056.
12 Rialon KL,Murillo R,Fevurly RD,et al.Impact of screening for hepatic hemangiomas in patients with multiple cutaneous infantile hemangiomas[J].Pediatr Dermatol,2015,32(6):808-812.DOI:10.1111/pde.12656.
13 Leaute-Labreze C,Dumas de la Roque E,Hubiche T,et al.Propranolol for severe hemangiomas of infancy[J].N Engl J Med,2008,358(24):2649-2651.DOI:10.1056/NEJMc0708819.
14 Kim KH,Choi TH,Choi Y,et al.Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma:a randomized clinical trial[J].JAMA Dermatol,2017,153(6):529-536.DOI:10.1001/jamadermatol.2017.0250.
15 Ji Y,Chen S,Xu C,et al.The use of propranolol in the treatment of infantile haemangiomas:an update on potential mechanisms of action[J].Br J Dermatol,2015,172(1):24-32.DOI:10.1111/bjd.13388.
16 Varrasso G,Schiavetti A,Lanciotti S,et al.Propranolol as first-line treatment for life-threatening diffuse infantile hepatic hemangioma:A case report[J].Hepatology,2017,66(1):283-285.DOI:10.1002/hep.29028.
17 Al Tasseh F,El-Khansa M,Abd O,et al.Diffuse hepatic hemangioma with single cutaneous hemangioma:an alerting occurrence[J].Clin Case Rep,2017,5(6):887-890.DOI:10.1002/ccr3.963.
Memo
收稿日期:2019-08-14。
基金项目:国家自然科学基金资助项目（编号：81401606/81400862）；四川大学优秀青年学者基金资助项目（编号：2015SU04A15）；四川省科技厅重点研发项目（编号：2019YFS0322）；四川大学华西医院临床孵化项目（编号：2019HXFH056）
通讯作者:吉毅,Email:jijiyuanyuan@163.com